PharmAbcine

Quick facts

Phase 1 pipeline

• PMC-309 Dose Expansion
• PMC-309 monotherapy
• PMC-403
• Tanibirumab · Other
• TTAC-0001 and pembrolizumab combination

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PharmAbcine portfolio CI brief
• PharmAbcine pipeline updates RSS